A Final Word on GPOs

Changes will likely come as a result of the intense public scrutiny that the GPO industry has been under for the past year, a scrutiny encouraged and to a large degree prompted by small medical device companies. The question of precisely in what ways leading GPOs will operate differently is, itself, an important part of the public debate. Yet, it's hard not to conclude that, no matter how GPOs reform themselves, the debate itself has left some fundamental questions on the table.

In this issue, we conclude the two-part series on the changes in group purchasing that will likely come as a result of the intense public scrutiny that the GPO industry has been under for the past year, a scrutiny encouraged and to a large degree prompted by small medical device companies.

The question of precisely in what ways leading GPOs will operate differently is, itself, an important part of the public...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.